• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Fulgent Genetics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/15/25 4:17:39 PM ET
    $FLGT
    Medical Specialities
    Health Care
    Get the next $FLGT alert in real time by email
    8-K
    false000167493000016749302025-05-152025-05-15

     

    !

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 15, 2025

     

    FULGENT GENETICS, INC.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware

    001-37894

    81-2621304

    (State or other jurisdiction of

    incorporation)

    (Commission File Number)

    (IRS Employer Identification No.)

     

    4399 Santa Anita Avenue

    El Monte, California

    91731

    (Address of Principal Executive Offices)

    (Zip Code)

     

    (626) 350-0537

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    FLGT

     

    The Nasdaq Stock Market 
    (Nasdaq Global Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     


     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On May 15, 2025 at 9:00 a.m. Pacific Time, Fulgent Genetics, Inc. (the “Company”), held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), at the Company’s offices at 4399 Santa Anita Avenue, El Monte, California 91731. Of the Company’s 30,865,730 shares of common stock issued and outstanding and eligible to vote as of the record date of March 20, 2025, a quorum of 25,319,928 shares, or approximately 82% of the eligible shares, was present in person or represented by proxy. Each of the matters set forth below is described in detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on March 25, 2025. The following actions were taken at the Annual Meeting:

    Proposal 1

    Election of the following nominees as directors of the Company, each to serve until the 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified.

     

     

     

    Votes For

     

     

    Votes Withheld

     

     

    Broker Non-Vote

     

    Ming Hsieh

     

    19,305,664

     

     

     

    839,020

     

     

     

    5,175,244

     

    Michael Nohaile, Ph.D.

     

    16,003,908

     

     

     

    4,140,776

     

     

     

    5,175,244

     

    Regina Groves

     

    14,263,988

     

     

     

    5,880,696

     

     

     

    5,175,244

     

    Linda Marsh

     

    13,816,654

     

     

     

    6,328,030

     

     

     

    5,175,244

     

    Proposal 2

    Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

     

    Votes For

     

     

    Votes Against

     

     

    Votes Abstained

     

     

    Broker Non-Vote

     

     

    25,177,291

     

     

     

    114,793

     

     

     

    27,844

     

     

     

    —

     

    Proposal 3

    Approval, on a non-binding advisory basis, the compensation of the Company’s named executive officers.

     

    Votes For

     

     

    Votes Against

     

     

    Votes Abstained

     

     

    Broker Non-Vote

     

     

    16,269,463

     

     

     

    3,814,788

     

     

     

    60,433

     

     

     

    5,175,244

     

     

     


     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 15, 2025

    FULGENT GENETICS, INC.

     

     

     

     

     

    By:

     

    /s/ Paul Kim

     

    Name:

     

    Paul Kim

     

    Title:

     

    Chief Financial Officer

     

     


    Get the next $FLGT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FLGT

    DatePrice TargetRatingAnalyst
    12/7/2023$35.00Neutral
    UBS
    12/8/2022$65.00 → $40.00Overweight → Neutral
    Piper Sandler
    11/18/2022$45.00Outperform
    Raymond James
    8/25/2022$65.00Outperform
    Credit Suisse
    2/4/2022$80.00Overweight
    Piper Sandler
    1/25/2022$141.00 → $125.00Outperform
    Oppenheimer
    8/10/2021$55.00 → $65.00Underperform
    Credit Suisse
    8/5/2021$55.00Underperform
    Credit Suisse
    More analyst ratings

    $FLGT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO and Treasurer Kim Paul bought $1,596,470 worth of shares (100,000 units at $15.96), increasing direct ownership by 40% to 348,282 units (SEC Form 4)

      4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

      3/5/25 6:47:40 PM ET
      $FLGT
      Medical Specialities
      Health Care

    $FLGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Marsh Linda was granted 8,982 shares, increasing direct ownership by 48% to 27,641 units (SEC Form 4)

      4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

      5/19/25 7:29:07 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • Director Nohaile Michael was granted 4,491 shares, increasing direct ownership by 31% to 19,020 units (SEC Form 4)

      4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

      5/19/25 5:32:58 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • Director Groves Regina E was granted 8,982 shares, increasing direct ownership by 112% to 16,982 units (SEC Form 4)

      4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

      5/19/25 5:32:32 PM ET
      $FLGT
      Medical Specialities
      Health Care

    $FLGT
    SEC Filings

    See more
    • Fulgent Genetics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Fulgent Genetics, Inc. (0001674930) (Filer)

      5/15/25 4:17:39 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Fulgent Genetics Inc.

      SCHEDULE 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

      5/13/25 4:30:21 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Fulgent Genetics Inc.

      SCHEDULE 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

      5/6/25 4:04:55 PM ET
      $FLGT
      Medical Specialities
      Health Care

    $FLGT
    Leadership Updates

    Live Leadership Updates

    See more

    $FLGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $FLGT
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $FLGT
    Financials

    Live finance-specific insights

    See more
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance
    • Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

      PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year

      6/10/24 1:00:00 AM ET
      $FLGT
      $NEO
      Medical Specialities
      Health Care
      Precision Instruments
    • Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain

      After promising results from first-in-man studies with its novel Neural Ice™ technology, the Massachusetts-based company will use the capital to initiate pivotal clinical studies in both chronic and acute pain indications CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Brixton Biosciences, a spin-out from Massachusetts General Brigham and a clinical stage life sciences company developing novel therapies for chronic and acute pain, today announced that it closed a Series B funding round of $33M. The round was led by Schooner Capital with notable participation by SV Health Investors, Sparta Group, Excelestar Ventures,  PV Capital Management, and Catalyst Health Ventures.

      5/14/24 9:00:00 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Fulgent Genetics Inc.

      SC 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)

      11/5/24 4:46:55 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Fulgent Genetics Inc. (Amendment)

      SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

      1/23/24 4:13:58 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Fulgent Genetics Inc. (Amendment)

      SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

      1/26/23 8:52:11 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • Fulgent Reports First Quarter 2025 Financial Results

      Core Revenue of $73.5 million grows 16% year-over-year Reiterating Full Year 2025 Core Revenue Guidance of $310 million Non-GAAP income of $1.2 million, or $0.04 per share; GAAP loss of $11.5 million, or ($0.37) per share Ended Q1 with $814.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.60 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025. First Quarter 2025 Results: Total Revenue of $

      5/2/25 7:00:00 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

      Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2025 financial results before the market opens on Friday, May 2, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is a te

      4/10/25 4:05:00 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance
    • Fulgent Reports First Quarter 2025 Financial Results

      Core Revenue of $73.5 million grows 16% year-over-year Reiterating Full Year 2025 Core Revenue Guidance of $310 million Non-GAAP income of $1.2 million, or $0.04 per share; GAAP loss of $11.5 million, or ($0.37) per share Ended Q1 with $814.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.60 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025. First Quarter 2025 Results: Total Revenue of $

      5/2/25 7:00:00 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

      Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2025 financial results before the market opens on Friday, May 2, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is a te

      4/10/25 4:05:00 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

      Full Year Total Revenue of $283.5 million Full Year Core Revenue grows 7% year-over-year to $281.2 million Ended 2024 with $828.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.87 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Results: Total Revenue of $76.2 million Core Revenue1 grew 14% year-over-year to $76.0 million GAAP loss of $5.9

      2/28/25 7:00:00 AM ET
      $FLGT
      Medical Specialities
      Health Care

    $FLGT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Fulgent Genetics with a new price target

      UBS initiated coverage of Fulgent Genetics with a rating of Neutral and set a new price target of $35.00

      12/7/23 6:19:41 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • Fulgent Genetics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Fulgent Genetics from Overweight to Neutral and set a new price target of $40.00 from $65.00 previously

      12/8/22 7:45:09 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • Raymond James initiated coverage on Fulgent Genetics with a new price target

      Raymond James initiated coverage of Fulgent Genetics with a rating of Outperform and set a new price target of $45.00

      11/18/22 7:49:05 AM ET
      $FLGT
      Medical Specialities
      Health Care